The Minister of Health of Yemen and the Accompanying Delegation Paid a Visit to Health Institutes of Türkiye (TÜSEB) Aziz Sancar Research Center.
On July 28, 2025, the Minister of Health of Yemen, Dr. Qasem Mohammed BUHEYB, and the accompanying delegation paid a visit to TÜSEB Aziz Sancar Research Center (ASAM). Participants of the visit included H.E. Mohamed Saleh Ahmed TURIQ, Ambassador of Yemen to Ankara; Dr. Mohamed KADRI, Health Attaché of the Embassy of Yemen; Dr. Aziz Alper BİTEN, Director General for EU and Foreign Affairs of the Republic of Türkiye Ministry of Health; Dr. Celal Orhun ECEMİŞ, Head of the Americas, Africa and Middle East Department; Aras BAYRAM, EU Expert at the same department; Prof. Dr. Ateş KARA, Head of TÜSEB Türkiye Vaccine Institute; Prof. Dr. Burak CİVELEK, Head of TÜSEB Türkiye Cancer Institute; Engin UÇAR, Administrative Affairs Officer at ASAM; Dr. Adil TEMEL, Information Systems Coordinator; Sezin ÜNAL, Administrative Staff at TÜSEB Foreign Affairs Department; and Halil İbrahim KILIÇ, Data Processing and Control Officer at Türkiye Cancer Institute.
As part of the visit, comprehensive information was shared regarding TÜSEB’s institutional structure, scientific research capacity, and ongoing strategic projects.The delegation was given a tour of the Türkiye National Genome Center (TUGEM), operating under ASAM, as well as the Biobank established within the scope of this project, and the laboratories affiliated with Türkiye Cancer Institute and Türkiye Vaccine Institute. Detailed information was provided about the technical infrastructure of these facilities.
The delegation received detailed information particularly on smart drug applications, immunotherapies, CAR-T cell treatments, and ongoing vaccine development efforts. They also showed significant interest in the nationally and locally produced healthcare projects being carried out by Türkiye.
At the conclusion of the visit, Prof. Dr. Ateş KARA, Head of TÜSEB Türkiye Vaccine Institute, provided information on ongoing research related to nanotechnology-based vaccine prototypes. In addition, the delegation was introduced to an innovative approach developed for the administration of the BCG (Bacillus Calmette–Guérin / Tuberculosis) vaccine in the form of a transdermal patch.
